SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 289.5 CNY | +4.56% |
|
+11.53% | +58.79% |
| 26/04 | Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80% | MT |
| 25/04 | Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 11,263 | 11,076 | 22,715 | 36,070 | - | - |
| Enterprise Value (EV) 1 | 11,263 | 11,076 | 22,715 | 36,070 | 36,070 | 36,070 |
| P/E ratio | 57.5 x | 51.9 x | 94.5 x | 80.4 x | 53.9 x | 46.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 15.5 x | 17 x | 13.5 x | 11.7 x |
| EV / Revenue | - | - | 15.5 x | 17 x | 13.5 x | 11.7 x |
| EV / EBITDA | - | - | 62.8 x | 37 x | 27.5 x | 22.5 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | 13.4 x | 16.9 x | 12.8 x | 10.1 x |
| Nbr of stocks (in thousands) | 1,15,266 | 1,23,977 | 1,24,589 | 1,24,589 | - | - |
| Reference price 2 | 97.71 | 89.34 | 182.3 | 289.5 | 289.5 | 289.5 |
| Announcement Date | 19/04/22 | 19/04/23 | 18/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1,468 | 2,117 | 2,680 | 3,082 |
| EBITDA 1 | - | - | 361.4 | 976 | 1,312 | 1,606 |
| EBIT 1 | - | - | 276.5 | 503 | 744 | 857 |
| Operating Margin | - | - | 18.84% | 23.76% | 27.76% | 27.81% |
| Earnings before Tax (EBT) 1 | - | - | 265 | 500 | 741 | 858 |
| Net income 1 | 194.7 | 211.7 | 240 | 449 | 669 | 768 |
| Net margin | - | - | 16.36% | 21.21% | 24.96% | 24.92% |
| EPS 2 | 1.700 | 1.721 | 1.930 | 3.600 | 5.370 | 6.170 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19/04/22 | 19/04/23 | 18/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 14.8% | 21% | 23.8% | 21.5% |
| ROA (Net income/ Total Assets) | - | - | - | 17.7% | 20.6% | 18.8% |
| Assets 1 | - | - | - | 2,537 | 3,248 | 4,085 |
| Book Value Per Share 2 | - | - | 13.60 | 17.20 | 22.50 | 28.70 |
| Cash Flow per Share 2 | - | - | 2.550 | 6.960 | 9.400 | 11.80 |
| Capex 1 | - | - | 262 | 204 | 452 | 599 |
| Capex / Sales | - | - | 17.85% | 9.64% | 16.87% | 19.44% |
| Announcement Date | 19/04/22 | 19/04/23 | 18/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
289.5
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +58.79% | 4.99B | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| -10.56% | 5.13B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B | |
| -0.50% | 1.64B | |
| +0.07% | 1.59B |
- Stock Market
- Equities
- 300573 Stock
- Financials Shenyang Xingqi Pharmaceutical Co.,Ltd.